SCHEMBL5138077

SCHEMBL5138077

CCCCN(Cc1ccc(O)cc1)Cc1c(-c2ccccc2OC)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.39
BCHE P06276 2/20 0.38
BCL2L2 Q92843 1/20 0.38
CASR P41180 1/20 0.36
TSHR P16473 2/20 0.36
HTR1A P08908 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
PAX8 Q06710 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CRHR1 P34998 2/20 0.35
TAAR1 Q96RJ0 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135487 0.93 BCHE (0.38) C5AR1BCHEBCL2L2TSHRHTR1A
SCHEMBL5136254 0.92 C5AR1 (0.39) C5AR1BCHEBCL2L2CASRTSHR
SCHEMBL5136086 0.91 C5AR1 (0.41) C5AR1BCL2L2CASRHTR1AHTR2C
SCHEMBL5137101 0.91 BCHE (0.42) C5AR1BCHEBCL2L2CASRHTR1A
SCHEMBL5134684 0.91 C5AR1 (0.41) C5AR1BCHEBCL2L2CASRTSHR
SCHEMBL5136839 0.90 C5AR1 (0.42) C5AR1BCL2L2CASRTSHRHTR1A
SCHEMBL5135984 0.90 BCL2L2 (0.39) C5AR1BCHEBCL2L2CASRTSHR
SCHEMBL5136942 0.88 C5AR1 (0.46) C5AR1TSHRCRHR1HDAC1KDM4E
SCHEMBL5134767 0.88 MAPT (0.40) C5AR1BCL2L2HTR1AHTR2CHTR2B
SCHEMBL5136568 0.88 CRHR1 (0.38) C5AR1BCL2L2CASRTSHRHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed